Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracey G Simon

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Annals of Internal Medicine|July 8, 2024
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort StudyTracey G Simon, Daniel E Singer, Yichi Zhang, et al.
Hepatology Communications|November 1, 2017
MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD)Tracey G Simon, Uri Kartoun, Hui Zheng, et al.
Hepatology Communications|January 13, 2021
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysisZoe N Memel, Ashwini Arvind, Oluwatoba Moninuola, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 4, 2022
Cardiovascular Outcomes in Patients With Biopsy-proven Alcohol-related Liver DiseaseHannes Hagström, Maja Thiele, Rajani Sharma, et al.
United European Gastroenterology Journal|January 28, 2022
Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver diseaseHannes Hagström, Maja Thiele, Tracey G Simon, et al.
The Lancet. Gastroenterology & Hepatology|September 23, 2021
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysisAlessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
American Journal of Epidemiology|April 29, 2021
Cancer Risk in Patients With Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With HistopathologyRajani Sharma, Elizabeth C Verna, Tracey G Simon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 30, 2023
Antibiotic use and development of nonalcoholic fatty liver disease: A population-based case-control studyFahim Ebrahimi, Tracey G Simon, Hannes Hagström, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 22, 2020
Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and WomenXiao Luo, Wanshui Yang, Yanan Ma, et al.
The American Journal of Gastroenterology|December 16, 2025
Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 DiabetesJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Annals of Internal Medicine|July 8, 2024
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort StudyTracey G Simon, Daniel E Singer, Yichi Zhang, et al.
Hepatology Communications|November 1, 2017
MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD)Tracey G Simon, Uri Kartoun, Hui Zheng, et al.
Hepatology Communications|January 13, 2021
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysisZoe N Memel, Ashwini Arvind, Oluwatoba Moninuola, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 4, 2022
Cardiovascular Outcomes in Patients With Biopsy-proven Alcohol-related Liver DiseaseHannes Hagström, Maja Thiele, Rajani Sharma, et al.
United European Gastroenterology Journal|January 28, 2022
Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver diseaseHannes Hagström, Maja Thiele, Tracey G Simon, et al.
The Lancet. Gastroenterology & Hepatology|September 23, 2021
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysisAlessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
American Journal of Epidemiology|April 29, 2021
Cancer Risk in Patients With Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With HistopathologyRajani Sharma, Elizabeth C Verna, Tracey G Simon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 30, 2023
Antibiotic use and development of nonalcoholic fatty liver disease: A population-based case-control studyFahim Ebrahimi, Tracey G Simon, Hannes Hagström, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 22, 2020
Physical Activity and Risk of Hepatocellular Carcinoma Among U.S. Men and WomenXiao Luo, Wanshui Yang, Yanan Ma, et al.
The American Journal of Gastroenterology|December 16, 2025
Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 DiabetesJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
Pageof 13